The global epigenetics drugs and diagnostic technologies market size was valued at USD 5.24 billion in 2017 and is projected to expand at a CAGR of 19.7% over the forecast period. The high prevalence of cancer and other chronic diseases along with the rising geriatric population are some of the key factors expected to boost the market. Organizations, such as the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institute of Health (NIH) promote funding and support for R&D and product development exercises pertaining to the field of epigenetics. This factor is anticipated to further fuel the expansion.
The NIH funds epigenetics research through the Common Fund Epigenomics program, which actively provides support for research, worldwide. The rising need to understand epigenetic modifications at the molecular level and the development of therapeutic solutions are anticipated to motivate these organizations to fund R&D programs. In addition, endeavors such as the Epidemiology and Genomics Research Program (EGRP) in the NCI's Division of Cancer grants research initiatives owing to novel epigenetic research that serves as a driving force for market growth.
According to the estimations based on a 2011 - 2015 statistic report by the National Cancer Institute (NIH), the estimated number of cancer deaths in the U.S. is around 163.5 per 100,000 men and women per year. Incidence rate, mortality and survival statistics, information on cancer symptoms, risk factors, early detection, and early treatment are among the key factors for the high prevalence of the disease.
The International Cancer Genome Consortium (ICGC) is focusing on obtaining the genomic description, epigenomic changes, and transcriptomic changes in different types of tumors. The Encyclopedia of DNA Elements (ENCODE) project was launched by the U.S. national human genome research institute to identify all the human genome sequence functional elements.
The International Human Epigenome Consortium (IHEC), built by the NIH is also involved in the development of data generation and analysis, which can be made useful for epigenomic researchers. Majorly, epigenetics research is focused on the identification of treatment options for various types of tumors.
Reagents dominated the product segment of the epigenetics drugs and diagnostic technologies market in 2017. Histone and DNA modifiers are the major types of reagents. Epigenetic reagents are segmented into antibodies, PCR reagents, histones, primers, electrophoresis reagents, nucleic acid analysis reagents, buffers, and others.
PyroMark Q24 is one of the advanced reagents featuring advanced pyrosequencing chemistry to provide even better real-time sequence-based detection and quantification than before. The existence of a number of technology platforms facilitates analysis at the gene, protein, or cellular levels, which leads to innovation in the market.
The kits product segment was observed to be the fastest-growing segment over the forecast period. The ready-to-use kits are manufactured by many biotechnology companies for the detection of epigenetic modifications. Kits available in the market range from kits for nucleic acid purification, analysis of DNA methylation status, and detection of histone modifications by various enzymes to kits for chromatin immunoprecipitation.
Epigenetic diagnostic kits are used for the diagnosis of disorders due to epigenetic modifications in the early stages and during treatment to check the efficacy of therapeutics. They work on the basis of immunoprecipitation by the involvement of modification-specific monoclonal antibodies.
The technology segment can be categorized into DNA methylation, histone methylation, histone acetylation, large noncoding RNA, microRNA modification, and chromatin structures. DNA methylation was the largest segment in 2017. DNA methylation is the covalent addition of a methyl group in the cytosine ring, which leads to the inhibition of transcription. Sensitive bisulfite modification followed by PCR is performed called Methylation Sensitive PCR (MSP).
Real-time PCR for methylation detection, methyl light, and quantitative analysis of methylated alleles are the variations of MSP. Currently, quantitative methods, such as allele-specific bisulfite sequencing, southern-based method, bisulfite pyrosequencing, and bisulfite PCR followed by MALDI-TOF MS are also useful for DNA methylation. Technological advancements are increasingly enabling the assessment of locus-specific DNA methylation on a genome-wide scale.
Histone Acetylation is expected to witness the fastest growth over the forecast period. Their enhanced efficacy due to the introduction of novel mechanisms can be attributed to this growth. Histone acetylation is the enzymatic incorporation of an acetyl group into lysine residues.
Histone acetylation is involved in controlling cellular processes, such as gene silencing, chromatin transcription and dynamics, the progression of the cell cycle, differentiation, apoptosis, DNA replication, neuronal repression, nuclear import, and DNA repair. The enzymes involved in histone acetylation are Histone Acetyl Transferases (HATs) and the enzymes involved in deacetylation are Histone Deacetylases (HDACs).
Based on the type of epigenetic therapies, the market is segmented into Histone Deacetylase (HDAC) inhibitors and DNA Methyltransferase (DNMT) inhibitors. The DNMT inhibitors were the largest revenue-generating segment in 2017 owing to factors such as wide-scale availability in most regions. Furthermore, a high number of generics are available in this therapy class, which is anticipated to bode well for segment growth.
The HDAC inhibitors are estimated to be the fastest-growing segment over the forecast period, owing to factors such as the presence of a strong product pipeline and commercial availability of the maximum number of products. In addition, from 2014 to 2015 three HDAC inhibitors were launched in the market, which is further likely to accelerate the growth of this therapy class over the forecast period.
Oncology was the largest revenue-generating segment in 2017. The increasing prevalence of cancer and the number of deaths caused by cancer are expected to be a high rendering driver for this growth. Furthermore, this segment is projected to gain a major revenue share over the forecast period owing to the introduction of new products and the potential future commercialization of products currently in the pipeline.
Hypermethylation and epigenetic silencing are known as epimutations, occurring due to epigenetic changes. Epimutations have been known to be involved in the etiology of cancers. Extensive R&D for detecting epimutations, specifically related to the silencing of tumor suppressor genes and activation of oncogenes, is anticipated to create growth avenues.
Non-oncology is estimated to be the fastest-growing segment owing to rigorous R&D initiatives undertaken by private institutions and biopharmaceutical companies for the identification of epigenetic markers related to these disorders. Epigenetic modifications have been proved to be the base of metabolic, neurodegenerative, infectious diseases, and many other non-oncology disorders. Extensive research is undertaken by private institutions and biopharmaceutical companies for the detection of biomarkers for drug development.
North America is the dominant regional segment of this market. It held over 39.34% of the market share in 2017. The presence of government funding programs for ongoing research activities, better healthcare facilities, and a constantly growing geriatric population are some of the prominent driving factors. In addition, the Common Fund-supported programs in the U.S. are likely to boost the research activities for a broad range of oncology and non-oncology diseases including metabolic, inflammatory, cardiovascular, and other diseases.
The Asia Pacific is estimated to be the fastest-growing region over the forecast period owing to the rising disposable income, high unmet clinical needs, rising awareness about early diagnosis, and availability of effective treatment in emerging countries, such as India and China. The Asia Pacific is in limelight due to increasing cases of various types of cancers.
Growth in the geriatric population is one of the leading causes of the increasing cases of oncology and chronic diseases. This is expected to further boost the regional market. The R&D initiatives related to the analysis of epigenetic bases in various diseases are on the rise in this region. EpiGen Research Consortium based in the U.K. has extended its research facility in Singapore for research on chronic diseases such as diabetes and obesity.
Key market players are Roche Diagnostics; Thermo Fisher Scientific, Inc.; Eisai Co. Ltd.; Novartis AG; Illumina, Inc.; Merck Sharp & Dohme Corp; Qiagen; Abcam PLC; and Merck KGaA. The major players are focusing on collaborations, mergers and acquisitions, new product developments, and geographic expansion to increase their market share.
For instance, in March 2015, Illumina, Inc. collaborated with Merck Serono to develop a universal next-sequencing-based oncology diagnostic with an aim to further strengthen its position in the market. The collaboration will enable the companies to increase their market share and gain a prominent position in the market over the forecast period.
Base year for estimation
Actual estimates/Historical data
2014 - 2016
2018 - 2025
Revenue in USD Million & CAGR from 2018 to 2025
North America, Europe, Asia Pacific, Latin America, MEA
Revenue forecast, company share, competitive landscape, growth factors, and trends
U.S., Canada, U.K., Germany, China, Japan, India, Brazil, Mexico, South Africa
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global epigenetics drugs and diagnostics technologies market report based on the product, technology, type of therapy, application, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
ChIP Sequencing Kit
Whole Genomic Amplification Kit
Bisulfite Conversion Kit
RNA Sequencing Kit
Technology Outlook (Revenue, USD Million, 2014 - 2025)
Large Non-coding RNA
Type of Therapy Outlook (Revenue, USD Million, 2014 - 2025)
Histone Deacetylase (HDAC) Inhibitors
DNA Methyltransferase (DNMT) Inhibitors
Application Outlook (Revenue, USD Million, 2014 - 2025)
Regional Outlook (Revenue, USD Million, 2014 - 2025)
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.